Nā Hoʻohui Metabolic ma waena o nā maʻi maʻi (Mahele 1)

by Kauka Alex Jimenez | ʻO ke akua, maʻi Pain, Nā Kūlana i mālamaʻia, ʻO ka Health Health Intestinal, ʻO ke ola o Gut a me Intestinal, Health, Nā hōʻailona, Video, Viscerosomatic Reflex, Ka maika'i

Introduction

ʻO Kauka Alex Jimenez, DC, ke hōʻike nei i ke ʻano o ka hoʻopili ʻana i ka metabolic i ka hopena o ke kaulahao i nā maʻi maʻi maʻi nui i kēia pūʻulu 2-ʻāpana. Nui nā kumu i ko mākou olakino a maikaʻi. Hiki iā ia ke alakaʻi i nā kumu pilikia e pili ana i nā hōʻailona like me ka ʻeha i loko o nā ʻiʻo, nā hono, a me nā ʻāpana koʻikoʻi. Māhele 2 e hoʻomau i ka hōʻike ʻana i nā pili metabolic me nā maʻi maʻi nui. Ke haʻi aku nei mākou i kā mākou poʻe maʻi i nā mea lapaʻau i hōʻoia ʻia e hāʻawi ana i nā lāʻau lapaʻau i loaʻa no nā poʻe e loaʻa ana i nā maʻi maʻi e pili ana i nā pilina metabolic. Paipai mākou i kēlā me kēia maʻi i ka wā kūpono ma ke kuhikuhi ʻana iā lākou i nā lawelawe lapaʻau pili e pili ana i kā lākou ʻike a i ʻole nā ​​​​pono. Hoʻomaopopo a ʻae mākou he ala kupanaha ka hoʻonaʻauao ʻana i ka nīnau ʻana i nā nīnau koʻikoʻi o kā mākou mea hoʻolako ma ke noi a me ka ʻae a ka mea maʻi. Hoʻohana ʻo Dr. Jimenez, DC i kēia ʻike ma ke ʻano he lawelawe hoʻonaʻauao. Akahana

Pehea ka hoʻomā ʻana i ke kino

ʻO Kauka Alex Jimenez, DC, hāʻawi: No laila, eia ʻoe he pūʻulu wīwī o nā adipocytes ma ka ʻaoʻao hema, a laila ke hoʻomaka nei lākou e hoʻonui i ke kaumaha o ke kelepona, hiki iā ʻoe ke ʻike i kēlā mau macrophages, hele mai nā boogies ʻōmaʻomaʻo me ka nānā ʻana, me ka ʻōlelo ʻana, "E, he aha ka hana ma ʻaneʻi? ʻAʻole pono ke nānā aku.” No laila ke noiʻi nei lākou, a ke kumu kēia i ka make o ke kelepona kūloko; he ʻāpana wale nō ia o ka cascade inflammatory. No laila aia kekahi hana ʻē aʻe e hana nei ma aneʻi. ʻAʻole hele wale kēlā mau adipocytes ma muli o ka pōʻino; pili pinepine ia me ka he'e nalu calorie. No laila, hoʻopōʻino kēia mea momona i ka reticulum endoplasmic, e alakaʻi ana i ka ʻeha hou aʻe. ʻO ka mea a kēia mau cell a me nā adipocytes e hoʻāʻo nei e pale iā lākou iho mai ka glucose a me ka lipo toxicity.

A ʻo ka cell a pau, ʻo ka adipocyte cell, ke hana nei i kēia mau pāpale e hoʻāʻo nei e ʻōlelo, "E ʻoluʻolu, ʻaʻole hiki iā mākou ke lawe hou i ka glucose, ʻaʻole hiki iā mākou ke lawe hou i nā lipids." He hana pale ia i kapa ʻia ʻo ka insulin resistance. ʻAʻole ia he hana ʻino wale nō. ʻO ia ke ala o ke kino e hoʻāʻo ai e pale i ka glucose a me ka lipotoxicity. I kēia manawa, ʻoi aku ka nui o ka hoʻāla ʻana ma mua o nā adipocytes wale nō, ke hele nei ka ʻōnaehana. Ke hoʻomaka nei nā ʻiʻo a me nā ʻāpana ʻē aʻe e ʻike i ke kaumaha like o ka heʻe nalu calorie, e hoʻoulu ai i ka mumū a me ka make o ke kelepona. No laila ua like ka glucose a me ka lipotoxicity me ke ake momona i ka wā e pili ana i ke ake. A hiki iā ʻoe ke loaʻa e like me ka hele ʻana o ka momona momona i ka cirrhosis me ka make hepatocyte. ʻO ka hana like e hana nei i loko o nā ʻiʻo ʻiʻo. No laila, ʻike pono kā mākou mau ʻiʻo ʻiʻo iwi i ka make ʻana o ka cell ma hope o ka ʻāʻī a ʻike i ka waiho ʻana o ka momona.

ʻO ke ala maikaʻi loa e noʻonoʻo ai, ʻo ia hoʻi, nā bipi i hānai ʻia no ka ʻai ʻana a me ke ʻano o kā lākou hana ʻana i ke kinikini. No laila, ʻo ia ka momona momona. A i loko o ke kanaka, hiki iā ʻoe ke noʻonoʻo e pili ana i ka lilo ʻana o ka poʻe i ka sarcopenic i ko lākou lilo ʻana i mea kūʻē i ka insulin. He ʻano like ia i ka wā e hoʻāʻo ai ke kino o ke kino e pale iā ia iho mai ka glucolipotoxicity, e hoʻoulu ai i kahi pane ʻeha kūloko. E lilo ia i pane endocrine ke hoʻomaka ʻo ia e huli i nā ʻiʻo ʻē aʻe ma ka ʻaoʻao, inā ʻo ke ake, ka ʻiʻo, ka iwi, a i ʻole ka lolo; ʻo ia wale nō ka mea e hana nei; Aia lākou i loko o nā adipocytes visceral i hiki ke hana i loko o nā ʻiʻo ʻē aʻe. No laila ʻo kāu hopena paracrine. A laila hiki ke hele i viral, inā makemake ʻoe.

Hoʻopili ʻia ka ʻāhu me ke kū ʻana o ka insulin

ʻO Kauka Alex Jimenez, DC, hāʻawi: Loaʻa iā ʻoe kēia pane kūloko a me ka ʻōnaehana pro-inflammatory i hui pū ʻia me ka pale ʻana i ka insulin, e hoʻi ana i kēia ʻano hana pale i ka glucose a me ka lipotoxicity. Ma ʻaneʻi ʻoe e ʻike ai i ka paʻa ʻana o nā kīʻaha koko i loko o ko mākou mau aʻa i loko o ka loop o ka hoʻomoe momona a me ka make cell. No laila e ʻike ʻoe i nā kīʻaha koko leaky a me nā waihona momona, a ʻike ʻoe i ka pōʻino a me ka pro-atherogenesis. I kēia manawa, he mea kēia a mākou i wehewehe ai ma AFMCP no ka module cardiometabolic. A ʻo ia ka physiology ma hope o ka loaʻa ʻana o ka insulin. ʻIke ʻia kēia ʻo ka ʻenehana laka a me ka jiggle. No laila pono ʻoe e hoʻopaʻa i ka insulin i loko o ka insulin receptor ma luna., i kapa ʻia ʻo ka laka.

A laila aia kahi phosphorylation cascade i kapa ʻia ʻo ka jiggle a laila hana i kēia cascade e hoʻomaka ai i nā ala glucose-4 e wehe i nā mea hoʻokipa glucose-4 e komo i loko o ke kelepona i hiki ai ke lilo i ka glucose, a laila hoʻohana ʻia no ka ikehu. hana ʻia e ka mitochondria. ʻOiaʻiʻo, ʻo ke kūʻē ʻana o ka insulin kahi i paʻa ʻole ai kēlā mea hoʻokipa. A no laila ʻaʻole wale ʻoe e hoʻokomo i ka glucose i loko o ke kelepona no ka hana ʻana i ka ikehu, akā ke hāʻawi pū nei ʻoe i kahi kūlana hyper insulin ma ka ʻaoʻao. No laila, loaʻa iā ʻoe ka hyperinsulinemia a me ka hyperglycemia i kēia hana. No laila he aha kā mākou e hana ai no ia mea? ʻAe, ua hōʻike ʻia ka nui o nā meaʻai e hoʻomaikaʻi ai i ka laka a me nā mea e hoʻomaikaʻi ai i nā mea lawe glucose-4 e piʻi mai ana i ka ʻaoʻao.

ʻO nā mea hoʻohui Anti-Inflammatory e ho'ēmi i ka wela

ʻO Kauka Alex Jimenez, DC, hāʻawi: ʻIke ʻoe i kēia mau mea i helu ʻia ma aneʻi: vanadium, chromium, kinamona alpha lipoic acid, biotin, a me kekahi mea pāʻani hou, berberine. ʻO Berberine kahi hua kanu e hiki ke hoʻomaloʻo i nā hōʻailona pro-inflammatory mua. No laila he aha ka mea ma mua o kēia mau comorbidities pinepine a ʻo ia ka insulin dysfunction. ʻAe, he aha ka mea ma mua o ka hana ʻole o ka insulin i nā manawa he nui? ʻO ka mumū a i ʻole ka ʻona. No laila inā kōkua ʻo berberine i ka pilikia ʻeha mua, e hoʻoponopono ia i ka pale ʻana o ka insulin i lalo a me nā comorbidities āpau e hiki mai. No laila e noʻonoʻo i ka berberine i kāu koho. No laila, hōʻike kēia iā ʻoe inā hiki iā ʻoe ke hōʻemi i ka mumū ma luna o luna, hiki iā ʻoe ke hōʻemi i nā hopena cascade he nui i lalo. ʻO Berberine ka mea e hana ma ka papa microbiome. Hoʻololi ia i ka microbiota gut. Hiki iā ia ke hana i kekahi pale pale pale, no laila ʻaʻole ia e hoʻonui i ka mumū.

No laila e noʻonoʻo ʻoe i ka berberine kekahi o nā mea hana e hiki ai iā ʻoe ke hoʻohana e kākoʻo i ka hana ʻole o ka insulin a me nā mea pili i ka insulin resistance-related comorbidities. Me he mea lā e hoʻonui ka Berberine i ka hōʻike ʻana i ka insulin, no laila ʻoi aku ka maikaʻi o ka laka a me ka jiggle a hoʻomaikaʻi i ka cascade me nā mea lawe glucose-4. ʻO ia kahi hana e hiki ai iā ʻoe ke hoʻomaka e ʻimi i ke kumu kumu o nā kūlana he nui a mākou i kūkākūkā ai ke ʻike ʻoe i ka paracrine a me ka endocrine glucose toxicity, lipotoxicity kino kino. I kēia manawa, ʻo kahi ʻano hana ʻē aʻe āu e noʻonoʻo ai ʻo ka hoʻohana ʻana i ka NF kappa B. No laila ʻo ka pahuhopu e hoʻopaʻa i ka NF kappa B no ka mea ʻaʻole lākou e unuhi, ʻaʻole e hoʻāla ʻia ka nui o nā hōʻailona mumū.

No laila, ʻo kā mākou pahuhopu e hoʻomau i ka NF kappa B. Pehea e hiki ai iā mākou ke hana pēlā? ʻAe, hiki iā mākou ke hoʻohana i ka NF kappa B inhibitors. No laila, i kēia hōʻike ʻana i nā koho lapaʻau no nā comorbidities e pili ana i ka insulin dysfunction, nui nā ala e hōʻemi ai i kēia mau kūlana overlapping e pili ana i ko mākou kino. No laila hiki iā ʻoe ke hoʻopili pololei i ka hoʻoikaika ʻana i ka insulin ma o nā mea hoʻohui anti-inflammatory a i ʻole ke kōkua ʻole i ka pale ʻana i ka insulin a i ʻole ka hana ʻole o ka insulin ma o ka hoʻohana ʻana i nā mea kūʻē i ka mumū. No ka mea inā ʻoe e hoʻomanaʻo, ʻo ka insulin dysfunction ka mea e hoʻokau ai i kēlā mau comorbidities. Akā ʻo ke kumu o ka hana ʻole ʻana o ka insulin i ka maʻamau a i ʻole nā ​​toxins. No laila ʻo kā mākou pahuhopu e hoʻoponopono i nā mea pro-inflammatory. No ka mea inā hiki iā mākou ke hoʻoponopono i nā mea pro-inflammatory a hoʻopaʻa i ka hana ʻole o ka insulin i ka ʻōpuʻu, hiki iā mākou ke pale i ka pōʻino o ke kino o lalo a i ʻole ka hana kino.

E hoemi ana i ka pehu ma ke kino

ʻO Kauka Alex Jimenez, DC, hāʻawi: E neʻe kāua i ka ʻāpana aʻe e hiki ai iā ʻoe ke hoʻoemi a hōʻemi paha i ka ʻāʻī a me ka pōʻino o ka sopa insulin inā makemake ʻoe, e ʻauʻau nā genes i ke kino. ʻO kēia ka mea āu e lohe pinepine ai i kā mākou hōʻikeʻike, a no ka mea, ma ka lāʻau lapaʻau hana, kōkua mākou e hoʻoponopono i ka ʻōpū. Ma laila ʻoe e hele ai. A ʻo kēia ka pathophysiology no ke kumu e hana ai mākou i ka lāʻau cardiometabolic. No laila inā loaʻa iā ʻoe kēlā meaʻai ʻilihune a kaumaha paha, ʻo kēlā ʻai komohana komohana me nā momona maikaʻi ʻole, e hōʻino pololei ia i kāu microbiome. Hiki i kēlā hoʻololi i ka microbiome ke hoʻonui i ka permeability intestinal. A i kēia manawa hiki i nā lipopolysaccharides ke unuhi a kahe paha i loko o ke kahe koko. I kēlā manawa, ʻōlelo ka ʻōnaehana immune, "ʻAʻole, e ka hoaaloha. ʻAʻole pono ʻoe e komo ma ʻaneʻi. Loaʻa iā ʻoe kēia mau endotoxins ma laila, a i kēia manawa aia kahi pane ʻino kūloko a me ka systemic e hoʻokau i ka ʻeha i ka insulin dysfunction, ka mea e hoʻoulu ai i nā maʻi metabolic e hiki mai ana ma hope o kēlā.

ʻO nā mea a pau e pili ana i ke kanaka, e kaomi ʻia ma ka epigenetically. No laila e hoʻomanaʻo, inā hiki iā ʻoe ke hoʻopau i ka ʻāʻī i loko o ka microbiome, ʻo ia hoʻi ka hana ʻana i kēia microbiome hoʻomanawanui a ikaika, hiki iā ʻoe ke hōʻemi i ka leo inflammatory o ke kino holoʻokoʻa. A ke hōʻemi ʻoe i kēlā, ua hōʻike ʻia e hoʻonohonoho i ka ʻike insulin. No laila ʻoi aku ka haʻahaʻa o ka mumū, ʻoi aku ka kiʻekiʻe o ka naʻau o ka insulin e pili ana i ka microbiome. No laila kahaha, ua hōʻike ʻia e pili ana nā probiotics me ka hoʻomaikaʻi ʻana i ka ʻike insulin. No laila, ʻo nā probiotics kūpono e hana i ka pale ʻana. Loaʻa ka ikaika a me ka modulation microbiome me nā probiotics. A no laila mālama ʻia a hoʻihoʻi hou ʻia ka ʻike insulin ma muli o kou wahi. No laila e ʻoluʻolu e noʻonoʻo ʻoe ma ke ʻano he ʻano hana ʻē aʻe a i ʻole ke koho lapaʻau no ka hoʻohana ʻana i ke olakino cardiometabolic no nā maʻi.

Probiotics

ʻO Kauka Alex Jimenez, DC, hāʻawi: No laila e pili ana i ka probiotics, e hoʻohana mākou iā ia i kekahi mea i loaʻa pū kekahi i ka maʻi irritable bowel a i ʻole nā ​​​​mea ʻai. Hiki iā mākou ke koho i nā probiotics ma luna o ka NF kappa B inhibitors inā loaʻa iā lākou nā pilikia kūʻē i ka insulin. Akā inā loaʻa iā lākou nā pilikia neurocognitive, hiki iā mākou ke hoʻomaka me ka NF kappa B. No laila, ʻo ia ke ala e hiki ai iā ʻoe ke hoʻoholo i nā mea e koho ai. I kēia manawa, e hoʻomanaʻo, i ka wā e kamaʻilio ai me nā maʻi, he mea nui e kūkākūkā i ke ʻano o kā lākou ʻai ʻana e hoʻoulu ai i ko lākou kino. He mea nui hoʻi e hoʻomaopopo ʻaʻole ia he kamaʻilio maikaʻi wale nō; he kamaʻilio nui a he kamaʻilio immune.

Hoʻomanaʻo kēia iā ʻoe i ka wā e hoʻoponopono ai ʻoe i ka ʻōpū ma ka hānai maikaʻi ʻana a me ka hoʻohaʻahaʻa ʻana i kona leo inflammatory, loaʻa iā ʻoe ka nui o nā pono pale ʻē aʻe; hooki a hoemi paha i ka ikaika o ka hana ole. A hiki iā ʻoe ke ʻike i kēlā, hiki i ka hopena ke hōʻemi i ka hopena overlapping o ka momona, ka maʻi diabetes, a me ka metabolic syndrome. Ke hoʻāʻo nei mākou e hoʻokele i ka home ʻo metabolic endotoxemia, a i ʻole ka hoʻokele wale ʻana i ka microbiome, he mea hana ikaika ia e kōkua ai i kāu mau maʻi kūʻē i ka insulin a i ʻole cardiometabolic. ʻO ka nui o nā ʻikepili e haʻi mai iā mākou ʻaʻole hiki iā mākou ke kamaʻilio e pili ana i ka ʻai pono a me ka hoʻoikaika kino.

ʻOi aku ma mua o kēlā. No laila, ʻoi aku ka maikaʻi o ka hoʻomaikaʻi ʻana i ka microbiota o ka ʻōpū, hiki iā mākou ke hoʻololi i nā hōʻailona ʻula ma o ka ʻai kūpono, ka hoʻomaʻamaʻa, ka mālama ʻana i ke kaumaha, ka hiamoe, nā mea ʻē aʻe a pau a mākou e kamaʻilio nei, a me ka hoʻoponopono ʻana i nā ʻāʻī a me nā niho. ʻO ka liʻiliʻi o ka mumū, ʻoi aku ka liʻiliʻi o ka insulin dysfunction a, no laila, ʻoi aku ka liʻiliʻi o kēlā mau hopena maʻi ma lalo. No laila ʻo ka mea a mākou e makemake ai e ʻike ʻoe e hele i ka ʻōpū a e hōʻoia i ka hauʻoli a me ka hoʻomanawanui ʻana o ka microbiome ʻōpū. ʻO ia kekahi o nā ala ikaika loa e hoʻohuli i kahi phenotype cardiometabolic olakino. A ma waho aʻe, ʻoiai he mea ʻoi aku ka nui o nā makahiki he ʻumi i hala aku nei, hana nā mea ʻala ʻala non-caloric e like me ka mea ʻole ka caloric. A no laila hiki ke hoʻopunipuni ʻia ka poʻe i ka manaʻo ʻana ʻaʻole ke kō.

Akā, eia ka pilikia. Hiki i kēia mau mea ʻono kūlohelohe ke hoʻopilikia i nā haku microbiome olakino a hoʻoulu i nā ʻano phenotype ʻelua. No laila, ʻoiai ke manaʻo nei ʻoe e loaʻa ana iā ʻoe ka pōmaikaʻi me ka loaʻa ʻole o nā calorie, e hoʻonui ana ʻoe i kou pilikia no ka maʻi maʻi ma muli o kona hopena i ka microbiome ʻōpū. ʻAe, ua hoʻokō mākou ma o ka pahuhopu hoʻokahi. Lana ka manaʻolana, ua aʻo ʻoe e pili ana ka insulin, ʻulaʻula, adipokines, a me nā mea ʻē aʻe a pau i hana ʻia i ka pane endocrine e pili ana i nā kino he nui. No laila, e hoʻomaka kākou e nānā i nā hōʻailona pilikia e puka mai ana. ʻAe, ua kamaʻilio iki mākou no TMAO. Eia hou, ʻo ia kahi manaʻo kūpono ma aneʻi me ka ʻōpū a me ka pale ʻana i ka insulin. No laila makemake mākou e hōʻoia ʻoe e nānā iā TMAO ʻaʻole ʻo ia ka hopena āpau akā ʻo kahi mea biomarker hou e hiki ke hāʻawi iā ʻoe i kahi ʻike e pili ana i ke olakino microbiome ma ka laulā.

Ke ʻimi nei i nā hōʻailona ʻā

ʻO Kauka Alex Jimenez, DC, hāʻawi: Nānā mākou i ka TMAO kiʻekiʻe e kōkua i ka mea maʻi e ʻike ua hoʻololi lākou i kā lākou ʻai. ʻO ka hapa nui o ka manawa, kōkua mākou i nā maʻi e hōʻemi i nā protein holoholona maikaʻi ʻole a hoʻonui i kā lākou mea kanu. ʻO ka maʻamau ka nui o nā kauka e hoʻohana iā ia i ka hana lapaʻau maʻamau. ʻAe, i kēia manawa kekahi biomarker e puka mai nei, ʻae, a he mea ʻakaʻaka ke kapa ʻia ʻo ia e puka mai ana no ka mea he mea maopopo loa, a ʻo ia ka insulin. Hoʻopili ʻia kā mākou maʻamau o ka mālama ʻana a puni ka glucose, ka glucose hoʻokēʻai, i kā mākou postprandial glucose A1C ma ke ʻano he ana o ka glucose. He glucose nui mākou a makemake mākou i ka insulin ma ke ʻano he biomarker e kū mai ana inā e hoʻāʻo mākou e pale a hoʻoikaika.

A ke hoʻomanaʻo nei ʻoe, ua kamaʻilio mākou i nehinei ʻo ka hoʻokē ʻai ʻana i ka insulin ma lalo o ka quartile mua o kāu pae kuhikuhi no ka insulin hoʻokēʻai ma kahi āu e makemake ai e hele. A no mākou ma US, ʻo ia ka mea ma waena o ʻelima a ʻehiku ma ke ʻano he ʻāpana. No laila e hoʻomaopopo ʻo ia ka pathophysiology o ka maʻi diabetes type ʻelua. No laila, hiki i ke ʻano maʻi diabetes ʻelua ke loaʻa mai ka pale ʻana i ka insulin; hiki ke loaʻa mai nā pilikia mitochondrial. No laila ʻo ka pathophysiology o ka maʻi maʻi type ʻelua no ka mea ʻaʻole huna kāu pancreas i ka nui o ka insulin. Eia hou, ʻo ia ka 20% liʻiliʻi a mākou e kamaʻilio nei e pili ana i ka hapa nui o ka poʻe e loaʻa ana i ka maʻi diabetes ʻano ʻelua; mai ka pale ʻana i ka insulin, e like me kā mākou e manaʻo ai, mai kahi pilikia hyper insulin. Akā aia kēia pūʻulu o ka poʻe i hōʻino i ka mitochondria, a ʻaʻole lākou e hoʻopuka i ka insulin.

No laila, piʻi aʻe ko lākou koko koko, a loaʻa iā lākou ka maʻi diabetes type ʻelua. ʻAe, a laila ʻo ka nīnau, inā he pilikia me nā cell beta pancreatic, no ke aha he pilikia? Ke piʻi aʻe nei ka glucose no ka loaʻa ʻana o ka insulin resistance o nā ʻiʻo, no laila ʻaʻole hiki iā lākou ke hopu a lawe mai i ka glucose? No laila, ʻo ke akepaʻa ka insulin hepatic hiki ʻole ke lawe i ka glucose no ka ikehu? No ke aha e holo ai kēia glucose i loko o ke koko? ʻO ia ka mea e hoʻohālikelike nei. No laila e hāʻawi i ka hana, pono ʻoe e nānā i nā adipocytes; pono ʻoe e ʻimi i ka adiposity visceral. Pono ʻoe e ʻike inā he mea hoʻomake like ʻole kēia kanaka. He aha kā mākou e hana ai e hōʻemi i kēlā? Mai ka microbiome mai ka mumū?

Panina

ʻO Kauka Alex Jimenez, DC, hāʻawi: Hiki i ke kīkī ke hana i kēia, ʻeā? E like paha me ka hoʻonui ʻana i ka glucose reabsorption. No ke aha mai? Ma muli paha o ke koʻikoʻi oxidative i paʻi i ka puʻupaʻa, a i ʻole ma ka axis HPA, ka hypothalamus pituitary adrenal axis kahi āu e loaʻa ai kēia pane cortisol a me kēia pane ʻōnaehana sympathetic e hoʻoulu ana i ka mumū a hoʻokele i ka insulin koko a pilikia koko koko? Ma ka Māhele 2, e kamaʻilio mākou ma ʻaneʻi e pili ana i ke ake. He mea pāʻani maʻamau ia no nā poʻe he nui, ʻoiai inā ʻaʻole lākou i loaʻa i ka maʻi fulminant fatty ate; he mea pāʻani maʻalahi a maʻamau no ka poʻe me ka maʻi cardiometabolic. No laila e hoʻomanaʻo, ua loaʻa iā mākou ka visceral adiposity e hoʻoulu ai i ka ʻeha a me ka pale ʻana i ka insulin me ka atherogenesis, a ua like ke ake me kēia kanaka hala ʻole i hopu ʻia i ka pāʻani. Ke hana nei ia ma mua o ka hoʻomaka ʻana o ka atherogenesis.

Akahana